Developer docs
API playgroundTry for free, no card

Search company profiles

Gelmedix

Full company profile

uuid0003f5a

Namestring
Gelmedix
Legal namestring
GelMEDIX, Inc.
Websiteurl
gelmedix.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

GelMEDIX is a privately held, pre-clinical biotechnology company founded in 2020 and headquartered in Cambridge, Massachusetts. The company is developing regenerative vision therapies built on a proprietary injectable hydrogel scaffold platform designed to protect therapeutic cells during injection, localize them to target tissues, and promote tissue regeneration while degrading naturally as new tissue forms. The technology is engineered to address core failure modes in cell and gene therapy delivery — specifically poor cell survival and engraftment — by providing a regenerative scaffold that integrates with newly formed tissue at the disease site.

The company's lead program, GMX-101, combines iPSC-derived retinal pigment epithelial (RPE) cells with the hydrogel scaffold to restore vision in patients with late-stage Geographic Atrophy (GA), a progressive form of dry age-related macular degeneration causing irreversible central vision loss in adults over 60. GelMEDIX is also positioning the hydrogel scaffold as a licensable delivery platform for stem cell-derived therapies developed by external pharmaceutical partners, with stated ambitions to extend beyond ophthalmology into other degenerative disorders. Preclinical efficacy in RPE cell transplantation has been demonstrated in ARVO Annual Meeting presentations across 2023, 2024, and 2025.

GelMEDIX operates a B2B, partnership-driven business model and does not yet have commercialized products. Future revenue is expected to flow from licensing and milestone payments under pharmaceutical partnerships, contract development and manufacturing arrangements, and ultimately from commercialization of proprietary cell therapies such as GMX-101. The company has raised approximately $13 million in a seed financing round led by Safar Partners (closed February 2026), with prior equity from HTL Biotechnology (2022), a $3.5M exempt offering (2024), and angel groups. Strategic partnerships with a global pharmaceutical company (February 2026) and Catalent (March 2026) anchor the commercial development pathway.

Short descriptiontext

GelMEDIX is a pre-clinical biotech developing an injectable hydrogel scaffold platform to improve cell and gene therapy delivery, with lead program GMX-101 (iPSC-derived RPE cell therapy) targeting late-stage Geographic Atrophy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
injectable hydrogel scaffolds, regenerative cell therapy, ophthalmic biomaterials, retinal pigment epithelium, biologics drug delivery
Industry3 codes
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

GelMEDIX generates revenue through licensing its proprietary hydrogel scaffold technology to pharmaceutical partners, including milestone payments and potential future revenue streams. The company announced its first strategic collaboration with a global pharmaceutical company involving supplying hydrogel technology for use with the partner's stem cell-derived cell lines.

tipranks.com
2Contract Development and Manufacturing
TypeProfessional Services
Description

Partnership with Catalent for development and clinical manufacturing of iPSC-derived cell therapies. While this is primarily for advancing GelMEDIX's own pipeline, it establishes manufacturing capabilities that could support future commercial partnerships.

bioinformant.com
3Pipeline Development and Milestones
TypeLicensing Royalties
Description

Advancing lead program GMX-101 through clinical development. Potential revenue from achieving development milestones, regulatory approvals, and commercialization of proprietary cell therapies.

tipranks.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GelMEDIX is a pre-clinical biotechnology company developing a proprietary injectable hydrogel scaffold platform engineered to improve the functional replacement and integration of therapeutic cells and the delivery of gene therapies. The platform protects cells during injection, localizes them to target sites, and provides a regenerative structure that degrades naturally over time as new tissue forms. Its lead program, GMX-101, combines iPSC-derived retinal pigment epithelial (RPE) cells with the hydrogel technology to restore vision in late-stage Geographic Atrophy patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • GMX-101 demonstrated significant vision preservation in preclinical studies while eliminating risks associated with other RPE cell therapies
Product overview1 text field

GelMEDIX is a biotechnology company developing regenerative vision therapies based on a proprietary injectable hydrogel scaffold platform. The platform is designed to optimize the delivery, efficacy, and safety of cell and gene therapies. The company's lead product is GMX-101, an iPSC-derived RPE cell therapy for late-stage Geographic Atrophy, which combines the hydrogel scaffold with therapeutic cells to restore vision. The company is building a pipeline of next-generation therapies for degenerative eye diseases and forging strategic partnerships to advance cell and gene therapies for other degenerative disorders.

Product and service1 record
1GMX-101 RPE Cell Therapy
CategoryCell Therapy
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2026-03-11
Description

Global partnership for development and clinical manufacturing of iPSC-derived cell therapies targeting ocular and retinal diseases. Catalent provides GMP-compliant induced pluripotent stem cell lines and manufacturing capabilities, including process development, analytical development, process scale-up, and GMP manufacturing support through all clinical stages. The partnership is designed to accelerate GelMEDIX's progress toward clinical trials.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

GelMEDIX announced its first strategic collaboration with a global pharmaceutical company to leverage GelMEDIX's injectable hydrogel scaffold technology for developing stem cell-derived cell therapies. The partnership involves supplying GelMEDIX's hydrogel technology for use with the partner's stem cell-derived cell lines, creating potential future revenue and milestone streams.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Existing CDMO partner of GelMEDIX and one of the largest cell therapy contract manufacturers; relevant as a strategic enabler of GelMEDIX's manufacturing pathway and an indicator of CDMO-led cell therapy trends.

TypeBroad incumbent
Description

AAV gene therapy platform with ophthalmology and rare disease programs (ABBV-RGX-314 for wet AMD/diabetic retinopathy); a broader gene therapy delivery company relevant to the gene therapy half of GelMEDIX's platform thesis.

TypeDirect peer
Description

Develops intravitreal gene therapies for wet AMD and other ocular diseases; comparable as an ocular-delivery-focused platform company working on retinal therapeutics.

TypeDirect peer
Description

Develops OpRegen, an allogeneic RPE cell therapy for dry AMD/geographic atrophy; the most direct clinical-stage peer competing in the same indication with a similar cell-replacement approach.

TypeDirect peer
Description

Markets Syfovre, the first FDA-approved treatment for geographic atrophy; defines the current standard of care that any late-stage GA therapy must differentiate against.

TypeDirect peer
Description

Acquired Iveric Bio for Izervay, another approved GA therapy, and has historically pursued RPE regenerative approaches (notably via the Ocata acquisition); a key competitor and potential strategic acquirer in the GA space.

TypeDirect peer
Description

Bayer-owned pluripotent stem cell therapy developer with programs in ophthalmology (RP) and other regenerative indications; directly comparable as a cell-therapy platform company advancing iPSC-derived therapeutics into the clinic.

8ViaCyte
TypeEmerging player
Description

Pioneer in stem cell-derived cell therapies (now part of Vertex) with deep expertise in iPSC manufacturing and engraftment; comparable as a platform cell-therapy peer with shared delivery/encapsulation challenges.

TypeDirect peer
Description

Clinical-stage biotech developing non-viral gene therapies for ophthalmic diseases using a proprietary electro-transfection delivery platform; comparable as an ocular therapeutics delivery-focused company.

TypeBroad incumbent
Description

Markets Eylea, the dominant anti-VEGF therapy for retinal diseases including wet AMD; a large incumbent shaping the retinal therapeutics market that any new entrant must compete against or partner with.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gelmedix

Ophthalmic Biologicsgelmedix.com

GelMEDIX is a pre-clinical biotech developing an injectable hydrogel scaffold platform to improve cell and gene therapy delivery, with lead program GMX-101 (iPSC-derived RPE cell therapy) targeting late-stage Geographic Atrophy.

What Gelmedix does

GelMEDIX is a privately held, pre-clinical biotechnology company founded in 2020 and headquartered in Cambridge, Massachusetts. The company is developing regenerative vision therapies built on a proprietary injectable hydrogel scaffold platform designed to protect therapeutic cells during injection, localize them to target tissues, and promote tissue regeneration while degrading naturally as new tissue forms. The technology is engineered to address core failure modes in cell and gene therapy delivery — specifically poor cell survival and engraftment — by providing a regenerative scaffold that integrates with newly formed tissue at the disease site.

The company's lead program, GMX-101, combines iPSC-derived retinal pigment epithelial (RPE) cells with the hydrogel scaffold to restore vision in patients with late-stage Geographic Atrophy (GA), a progressive form of dry age-related macular degeneration causing irreversible central vision loss in adults over 60. GelMEDIX is also positioning the hydrogel scaffold as a licensable delivery platform for stem cell-derived therapies developed by external pharmaceutical partners, with stated ambitions to extend beyond ophthalmology into other degenerative disorders. Preclinical efficacy in RPE cell transplantation has been demonstrated in ARVO Annual Meeting presentations across 2023, 2024, and 2025.

GelMEDIX operates a B2B, partnership-driven business model and does not yet have commercialized products. Future revenue is expected to flow from licensing and milestone payments under pharmaceutical partnerships, contract development and manufacturing arrangements, and ultimately from commercialization of proprietary cell therapies such as GMX-101. The company has raised approximately $13 million in a seed financing round led by Safar Partners (closed February 2026), with prior equity from HTL Biotechnology (2022), a $3.5M exempt offering (2024), and angel groups. Strategic partnerships with a global pharmaceutical company (February 2026) and Catalent (March 2026) anchor the commercial development pathway.

Gelmedix firmographics

Firmographics
Name
Gelmedix
Legal name
GelMEDIX, Inc.
Website
https://gelmedix.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
GelMEDIX is a pre-clinical biotech developing an injectable hydrogel scaffold platform to improve cell and gene therapy delivery, with lead program GMX-101 (iPSC-derived RPE cell therapy) targeting late-stage Geographic Atrophy.
Ownership category
akta.pro rank

Gelmedix industry classification

Industry
Product category
Ophthalmic Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Injectable hydrogel scaffolds
  • Regenerative cell therapy
  • Ophthalmic biomaterials
  • Retinal pigment epithelium
  • Biologics drug delivery

Where Gelmedix is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Gelmedix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

  1. Strategic Partnerships and Licensing: GelMEDIX generates revenue through licensing its proprietary hydrogel scaffold technology to pharmaceutical partners, including milestone payments and potential future revenue streams. The company announced its first strategic collaboration with a global pharmaceutical company involving supplying hydrogel technology for use with the partner's stem cell-derived cell lines.
  2. Contract Development and Manufacturing: Partnership with Catalent for development and clinical manufacturing of iPSC-derived cell therapies. While this is primarily for advancing GelMEDIX's own pipeline, it establishes manufacturing capabilities that could support future commercial partnerships.
  3. Pipeline Development and Milestones: Advancing lead program GMX-101 through clinical development. Potential revenue from achieving development milestones, regulatory approvals, and commercialization of proprietary cell therapies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Gelmedix product offering

Product offering

Core offering

GelMEDIX is a pre-clinical biotechnology company developing a proprietary injectable hydrogel scaffold platform engineered to improve the functional replacement and integration of therapeutic cells and the delivery of gene therapies. The platform protects cells during injection, localizes them to target sites, and provides a regenerative structure that degrades naturally over time as new tissue forms. Its lead program, GMX-101, combines iPSC-derived retinal pigment epithelial (RPE) cells with the hydrogel technology to restore vision in late-stage Geographic Atrophy patients.

Product overview

GelMEDIX is a biotechnology company developing regenerative vision therapies based on a proprietary injectable hydrogel scaffold platform. The platform is designed to optimize the delivery, efficacy, and safety of cell and gene therapies. The company's lead product is GMX-101, an iPSC-derived RPE cell therapy for late-stage Geographic Atrophy, which combines the hydrogel scaffold with therapeutic cells to restore vision. The company is building a pipeline of next-generation therapies for degenerative eye diseases and forging strategic partnerships to advance cell and gene therapies for other degenerative disorders.

Differentiator

Problem solved

Functional benefit

Products and services

  • GMX-101 RPE Cell Therapy

Quantifiable outcome

  • GMX-101 demonstrated significant vision preservation in preclinical studies while eliminating risks associated with other RPE cell therapies

Companies that use Gelmedix

Customer profile

Segments3 records

Ideal customer profiles2 records

Gelmedix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Gelmedix partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship.

  • CatalentflagshipTechnology or Integration · 11 March 2026Global partnership for development and clinical manufacturing of iPSC-derived cell therapies targeting ocular and retinal diseases. Catalent provides GMP-compliant induced pluripotent stem cell lines and manufacturing capabilities, including process development, analytical development, process scale-up, and GMP manufacturing support through all clinical stages. The partnership is designed to accelerate GelMEDIX's progress toward clinical trials.
  • Global Pharmaceutical Company (Unnamed)flagshipStrategic or Co-development Partner · 17 February 2026GelMEDIX announced its first strategic collaboration with a global pharmaceutical company to leverage GelMEDIX's injectable hydrogel scaffold technology for developing stem cell-derived cell therapies. The partnership involves supplying GelMEDIX's hydrogel technology for use with the partner's stem cell-derived cell lines, creating potential future revenue and milestone streams.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Gelmedix competitors and assessment

Company assessment

Others

  • Catalent: Existing CDMO partner of GelMEDIX and one of the largest cell therapy contract manufacturers; relevant as a strategic enabler of GelMEDIX's manufacturing pathway and an indicator of CDMO-led cell therapy trends.

Broad incumbents

  • REGENXBIO: AAV gene therapy platform with ophthalmology and rare disease programs (ABBV-RGX-314 for wet AMD/diabetic retinopathy); a broader gene therapy delivery company relevant to the gene therapy half of GelMEDIX's platform thesis.
  • Regeneron Pharmaceuticals: Markets Eylea, the dominant anti-VEGF therapy for retinal diseases including wet AMD; a large incumbent shaping the retinal therapeutics market that any new entrant must compete against or partner with.

Direct peers

  • Adverum Biotechnologies: Develops intravitreal gene therapies for wet AMD and other ocular diseases; comparable as an ocular-delivery-focused platform company working on retinal therapeutics.
  • Lineage Cell Therapeutics: Develops OpRegen, an allogeneic RPE cell therapy for dry AMD/geographic atrophy; the most direct clinical-stage peer competing in the same indication with a similar cell-replacement approach.
  • Apellis Pharmaceuticals: Markets Syfovre, the first FDA-approved treatment for geographic atrophy; defines the current standard of care that any late-stage GA therapy must differentiate against.
  • Astellas Pharma (Iveric Bio): Acquired Iveric Bio for Izervay, another approved GA therapy, and has historically pursued RPE regenerative approaches (notably via the Ocata acquisition); a key competitor and potential strategic acquirer in the GA space.
  • BlueRock Therapeutics: Bayer-owned pluripotent stem cell therapy developer with programs in ophthalmology (RP) and other regenerative indications; directly comparable as a cell-therapy platform company advancing iPSC-derived therapeutics into the clinic.
  • Eyevensys: Clinical-stage biotech developing non-viral gene therapies for ophthalmic diseases using a proprietary electro-transfection delivery platform; comparable as an ocular therapeutics delivery-focused company.

Emerging players

  • ViaCyte: Pioneer in stem cell-derived cell therapies (now part of Vertex) with deep expertise in iPSC manufacturing and engraftment; comparable as a platform cell-therapy peer with shared delivery/encapsulation challenges.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights6 records

Customer concentration

Gelmedix social profiles

Digital presence

Gelmedix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gelmedix leadership team

Management profile

Number of profiles

Profiles10 records

Gelmedix funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gelmedix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gelmedix

What does Gelmedix do?

GelMEDIX is a pre-clinical biotechnology company developing a proprietary injectable hydrogel scaffold platform engineered to improve the functional replacement and integration of therapeutic cells and the delivery of gene therapies. The platform protects cells during injection, localizes them to target sites, and provides a regenerative structure that degrades naturally over time as new tissue forms. Its lead program, GMX-101, combines iPSC-derived retinal pigment epithelial (RPE) cells with the hydrogel technology to restore vision in late-stage Geographic Atrophy patients.

Is Gelmedix a public or private company?

Gelmedix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Gelmedix founded?

Gelmedix was founded in 2020. It employs 1 to 10 people.

Where is Gelmedix based?

Gelmedix is headquartered in Cambridge, United States, in the North America region.

How does Gelmedix make money?

Three revenue lines are on record. Strategic Partnerships and Licensing is the primary driver. The others are contract Development and Manufacturing and pipeline Development and Milestones.

Who are Gelmedix's main competitors?

Catalent is listed as an others. Broad incumbents are REGENXBIO and Regeneron Pharmaceuticals. Direct peers are Adverum Biotechnologies, Lineage Cell Therapeutics, Apellis Pharmaceuticals, Astellas Pharma (Iveric Bio), BlueRock Therapeutics and Eyevensys. ViaCyte is listed as an emerging player.

Does Gelmedix have an API?

No public API is recorded for Gelmedix.

What industry is Gelmedix in?

Gelmedix's product category is Ophthalmic Biologics. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioinformantCatalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal DiseasesGelMEDIX Inc. and Catalent, Inc. announced a global partnership for the development and clinical manufacturing of iPSC-derived cell therapies targeting ocular and retinal diseases. Under the agreement, GelMEDIX will leverage Catalent's GMP-compliant induced pluripotent stem cell lines and manufacturing infrastructure to advance its vision-restoring therapies through clinical development. The partnership is designed to accelerate GelMEDIX's progression toward clinical trials for its lead programs focused on restoring vision in patients.BioSpaceCatalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal DiseasesGelMEDIX Inc. and Catalent, Inc. announced a global partnership for the development and clinical manufacturing of iPSC-derived cell therapies targeting ocular and retinal diseases. Under the agreement, GelMEDIX will access Catalent's GMP-compliant induced pluripotent stem cell lines and manufacturing capabilities to support its cell therapy programs from early development through all clinical stages. The partnership is intended to accelerate GelMEDIX's progress toward bringing its vision-restoring therapies into clinical trials.PharmiWeb.comCatalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal DiseasesGelMEDIX Inc. and Catalent, Inc. announced a global partnership for the development and clinical manufacturing of iPSC-derived cell therapies targeting ocular and retinal diseases. Under the agreement, GelMEDIX will access Catalent's GMP-compliant induced pluripotent stem cell lines and manufacturing capabilities to support its vision-restoring therapies through all clinical stages, starting with late-stage Geographic Atrophy. The early-stage partnership positions GelMEDIX to accelerate its progress toward clinical trials for its lead regenerative ophthalmology programs.ContractpharmaGelMEDIX, Catalent Partner to Advance iPSC-Derived Cell TherapiesGelMEDIX Inc., a biotechnology company developing regenerative cell therapies for ocular and retinal diseases, has partnered with Catalent Inc., a global contract development and manufacturing organization, to leverage Catalent's GMP-compliant iPSC lines and manufacturing capabilities. Under the agreement, Catalent will provide process development, analytical development, process scale-up, and GMP manufacturing support for GelMEDIX's iPSC-derived cell therapies from early development through all clinical stages. The partnership is intended to accelerate GelMEDIX's progress toward clinical trials for its lead vision-restoration programs.Pulse 2.0GelMEDIX: $13 Million Seed Funding Closed For Vision Restoration Biotechnology PlatformGelMEDIX has closed a $13 million seed financing round led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, and Boston Harbor Angels, to advance its lead program GMX-101, a retinal pigment epithelial cell therapy for late-stage Geographic Atrophy. The company also announced its first strategic collaboration with a global pharmaceutical company to apply its injectable hydrogel scaffold technology in combination with the partner's cell lines for stem cell-derived therapies. The financing includes the addition of two new board members from MIT and Safar Partners.citybizGelMEDIX Raises $13M Seed RoundGelMEDIX, Inc., a biotechnology firm focused on vision restoration therapies, announced it has completed a $13 million seed funding round led by Safar Partners, with multiple other investors participating. The funds will be used to advance their lead program, GMX-101, and develop their proprietary hydrogel scaffold platform, including a recent strategic partnership with a global pharmaceutical company.FinSMEsGelMEDIX Raises $13M in Seed FundingGelMEDIX, a Cambridge, Massachusetts-based biotechnology company developing regenerative therapies for vision restoration, raised $13 million in seed funding led by Safar Partners with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, and Boston Harbor Angels. The company plans to use the proceeds to advance its lead program GMX-101, a retinal pigment epithelial cell therapy targeting late-stage Geographic Atrophy. GelMEDIX also announced its first strategic collaboration with a global pharmaceutical company to provide its proprietary injectable hydrogel scaffold technology for stem cell-derived cell therapy development.PR NewswireGelMEDIX Completes $13 Million Seed Financing and Announces First PartnershipGelMEDIX, a biotechnology company developing regenerative vision therapies, completed a $13 million seed financing round led by Safar Partners with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, and Boston Harbor Angels. The company also announced its first strategic collaboration with a global pharmaceutical company to leverage GelMEDIX's hydrogel scaffold technology for developing stem cell-derived cell therapies. Proceeds will advance GelMEDIX's lead program GMX-101, an RPE cell therapy for late-stage Geographic Atrophy, a progressive form of dry age-related macular degeneration causing irreversible central vision loss.TipranksGelMEDIX Raises $13 Million Seed Round and Signs First Pharma Partnership to Advance Vision-Restoring Cell TherapiesGelMEDIX has secured $13 million in seed financing led by Safar Partners, with participation from angel investors, and simultaneously entered its first strategic collaboration with a global pharmaceutical company to develop regenerative cell therapies. The funding will advance GMX-101, GelMEDIX's lead retinal pigment epithelial cell therapy targeting Geographic Atrophy, and support further development of its injectable hydrogel scaffold platform designed to improve cell survival and engraftment in cell and gene therapies. The partnership involves supplying GelMEDIX's hydrogel technology for use with the partner's stem cell-derived cell lines, creating a potential future revenue and milestone stream.